Prospective study of the efficacy of imeglimin and metformin against insulin secretion and resistance in patients with type 2 diabetes

Hamamoto Yoshiyuki0 个研究点目标入组 40 人开始时间: 2022年8月16日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Patients with type 2 diabetes
•2) Tha age is more than 18 and less than 75
•3) Patients who receive no anit-diabetic drugs, oronly one kind of anit-diabetic drug; sulfonylurea, glinide, alpha-glucosidase inhibitor, DPP-4inhibitor, pioglitazone, or SGLT2 inhibitor.
•4) HbA1c 7.0-9.0%(Patients who receive no anit-diabetic drugs), HbA1c 6.0%-8.0% (Patients who re
•ceive only one kind of anit-diabetic drug
•5) BMI is more than 18kg/m2 and less than 35kg/m2
•6) Hb is more than 12.5g/dL (male) or 12.0g/dL (female)
•7) Patiets who agree to participate in this study by the agreement form

•1) Patients with renal dysfunction (eGFR is less than 45mL/min/1.73m2)
•2) Patients who receive metformin, imeglimin insulin, or GLP-1 receptor agonitst.
•3) Patients with hepatic dysfunction (AST, ALT, gammma-GTP is above 3 fold of ULN)
•4) Patients receiving SGLT2 inhibitors and diagnosed heart failure
•5) Severe retinopathy (Proliferative Diabetic Retinopathy or vitreous hemorrhage)
•6) Patients with a history of gastrointestinal surgery
•7) Patients with a history of malignancy within 5 years
•8) Patients with severe infection, perioperative, or severe trauma
•9) Patients with excessive drinking habits (more than 5 days a week)
•10) Patients who have difficulty following the instructions of the principal investigator or sub-investigator
•11) Patients who are participating in other clinicaltrials, clinical research, etc.
•12) Patients with other conditions that the responsible investigator or subinvestigators think inappropriate to participate in the study

发起方

Hamamoto Yoshiyuki